In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
As of close of business last night, Candel Therapeutics Inc’s stock clocked out at $6.96, up 4.35% from its previous closing price of $6.67. In other words, the price has increased by $4.35 from its previous closing price. On the day, 0.97 million shares were traded. CADL stock price reached its highest trading level at $7.12 during the session, while it also had its lowest trading level at $6.6007.
Ratios:
To gain a deeper understanding of CADL’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.64 and its Current Ratio is at 4.64. In the meantime, Its Debt-to-Equity ratio is 0.15 whereas as Long-Term Debt/Eq ratio is at 0.02.
On February 20, 2025, Citigroup started tracking the stock assigning a Buy rating and target price of $25.
On February 19, 2025, Canaccord Genuity started tracking the stock assigning a Buy rating and target price of $20.Canaccord Genuity initiated its Buy rating on February 19, 2025, with a $20 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jun 30 ’25 when Nichols William Garrett sold 781 shares for $5.04 per share. The transaction valued at 3,936 led to the insider holds 52,493 shares of the business.
WILLIAM GARRETT NICHOLS bought 3,593 shares of CADL for $17,606 on Jun 30 ’25. On Mar 18 ’25, another insider, Nichols William Garrett, who serves as the Chief Medical Officer of the company, sold 45,316 shares for $8.76 each. As a result, the insider received 396,995 and left with 52,493 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CADL now has a Market Capitalization of 348714784 and an Enterprise Value of 267462640.
Stock Price History:
The Beta on a monthly basis for CADL is -0.89, which has changed by 0.06912446 over the last 52 weeks, in comparison to a change of 0.17774606 over the same period for the S&P500. Over the past 52 weeks, CADL has reached a high of $14.60, while it has fallen to a 52-week low of $3.79. The 50-Day Moving Average of the stock is 24.77%, while the 200-Day Moving Average is calculated to be 9.58%.
Shares Statistics:
It appears that CADL traded 1.02M shares on average per day over the past three months and 1092050 shares per day over the past ten days. A total of 49.25M shares are outstanding, with a floating share count of 36.70M. Insiders hold about 31.18% of the company’s shares, while institutions hold 36.21% stake in the company. Shares short for CADL as of 1751241600 were 6580198 with a Short Ratio of 6.47, compared to 1748563200 on 5885529. Therefore, it implies a Short% of Shares Outstanding of 6580198 and a Short% of Float of 17.01.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
Investors are keenly observing as 2 analysts analyze and rate the current performance of Candel Therapeutics Inc (CADL) in the stock market.The consensus estimate for the next quarter is -$0.17, with high estimates of -$0.12 and low estimates of -$0.21.
Analysts are recommending an EPS of between -$0.53 and -$0.77 for the fiscal current year, implying an average EPS of -$0.65. EPS for the following year is -$0.62, with 1.0 analysts recommending between -$0.62 and -$0.62.
